Xencor XNCR Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Regeneron PharmaceuticalsREGN

$37.8M+24.8%

Janux TherapeuticsJANX

$2.55M+36.3%

AbCellera Biologics Inc.ABCL

$5.67M+15.8%

AnaptysBio, Inc.ANAB

$2.12M+8.1%

Immix Biopharma, Inc.IMMX

$125.39K+84.9%

Xenon PharmaceuticalsXENE

$1.34M-8.3%

FAQ

What is Xencor's operating lease liabilities (current)?

Xencor (XNCR) reported operating lease liabilities (current) of $3.92M in Q2 2026.

How has Xencor's operating lease liabilities (current) changed year-over-year?

Xencor's operating lease liabilities (current) increased by 15.9% year-over-year, from $3.38M to $3.92M.

What is the long-term trend for Xencor's operating lease liabilities (current)?

Over 5 years (2020 to 2025), Xencor's operating lease liabilities (current) has grown at a 11.6% compound annual growth rate (CAGR), from $1.89M to $3.26M.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.